Utility of Donor-Derived Cell Free DNA in Association With Gene Expression Profiling

Not Recruiting

Trial ID: NCT02178943


Plasma donor-derived cell-free DNA (dd-cfDNA) is measured as a % of the total plasma cfDNA in association with the measurement of AlloMap, a non-invasive gene expression test to aid in heart transplant management.

Official Title

Utility of Donor-Derived Cell-free DNA in Association With Gene-Expression Profiling (AlloMap®) in Heart Transplant Recipients (D-OAR)

Stanford Investigator(s)

Kiran Kaur Khush, MD
Kiran Kaur Khush, MD

Professor of Medicine (Cardiovascular Medicine)


Inclusion Criteria

   1. Any heart transplant recipient eligible for initiation and participation in the
   Outcomes AlloMap Registry (OAR) Study of regular AlloMap testing.

   2. Patients can be enrolled any time as long as they have not had more than 1 prior

   3. Written informed consent must be obtained prior to study enrollment. Exclusion

1. Pregnant Women.

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Helen Luikart